Microbiome mapping technology company Kanvas Biosciences has announced the acquisition of assets from California-based Federation Bio, bringing with it two active therapeutics programmes.
Kanvas Biosciences says the move allows it to transition from a tech company into a full-stack therapeutics company with active clinical programmes and a new cell banking facility in south San Francisco.
Go deeper with GlobalData
In addition to the two active therapeutics programmes, the deal comes with a microbial library and intellectual property from Federation Bio, allowing Kanvas Biosciences to fully enter the therapeutics industry.
Matthew Cheng, co-founder and CEO of Kanvas Biosciences, said: “Kanvas Biosciences is leading the way in understanding exactly how the microbiome benefits human health. This acquisition allows us to manufacture and clinically investigate complex microbial consortia much faster than previously envisioned.
“Rather than devote years to building a manufacturing process from the ground up, we are thrilled to be able to positively impact patients’ lives much faster by acquiring these key technologies.”
The two programmes included in the acquisition include the immuno-oncology programme, a standard therapy for many solid organ tumors such as melanoma, lung cancer and colon cancer.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe second is the Inflammatory Bowel Disease Programme, which is working to produce therapies for many diseases associated with the microbiome, including inflammatory bowel disease.
The acquisition comes after the announcement in February of this year of a strategic collaboration between the company and the University of Texas MD Anderson Cancer Center to develop a new microbiome treatment for immunotherapy-resistant cancer patients.
Cheng added: “The Kanvas Biosciences and Federation Bio teams have worked together synergistically for years on microbiome projects and I couldn’t be more excited about how much more we are going to accomplish with our combined platform technologies.”
As a result of this acquisition, Kanvas Biosciences has said that it is creating a first-in-category company capable of leveraging complex microbial therapies with hundreds of members simultaneously.
